AllianceBernstein
ABUS icon

AllianceBernstein’s Arbutus Biopharma ABUS Stock Holding History

AllianceBernstein’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Sell
127,340
-16,530
-11% -$72.3K ﹤0.01% 2539
2025
Q4 		$692K Hold
143,870
– – ﹤0.01% 2507
2025
Q3 		$653K Buy
143,870
+23,630
+20% +$86.8K ﹤0.01% 2542
2025
Q2 		$372K Hold
120,240
– – ﹤0.01% 2810
2025
Q1 		$420K Hold
120,240
– – ﹤0.01% 2625
2024
Q4 		$393K Sell
120,240
-17,380
-13% -$63.9K ﹤0.01% 2746
2024
Q3 		$530K Hold
137,620
– – ﹤0.01% 2636
2024
Q2 		$425K Buy
137,620
+41,580
+43% +$125K ﹤0.01% 2753
2024
Q1 		$248K Hold
96,040
– – ﹤0.01% 2875
2023
Q4 		$240K Buy
96,040
+4,940
+5% +$9.67K ﹤0.01% 2926
2023
Q3 		$185K Buy
91,100
+6,930
+8% +$14.5K ﹤0.01% 2982
2023
Q2 		$194K Buy
84,170
+26,870
+47% +$69.9K ﹤0.01% 2990
2023
Q1 		$174K Buy
57,300
+8,200
+17% +$23.1K ﹤0.01% 2944
2022
Q4 		$114K Buy
49,100
+17,300
+54% +$41.4K ﹤0.01% 3103
2022
Q3 		$61K Buy
31,800
+7,600
+31% +$17.9K ﹤0.01% 3167
2022
Q2 		$66K Buy
24,200
+10,100
+72% +$25.8K ﹤0.01% 3152
2022
Q1 		$42K Hold
14,100
– – ﹤0.01% 3183
2021
Q4 		$55K Hold
14,100
– – ﹤0.01% 3238
2021
Q3 		$60K Hold
14,100
– – ﹤0.01% 3221
2021
Q2 		$43K Buy
+14,100
New +$43.7K ﹤0.01% 3280
2018
Q4 		– Sell
-29,821
Closed -$282K – 3097
2018
Q3 		$282K Buy
+29,821
New +$296K ﹤0.01% 2873
2015
Q2 		– Sell
-500
Closed -$9K – 2995
2015
Q1 		$9K Hold
500
– – ﹤0.01% 3360
2014
Q4 		$8K Buy
+500
New +$8.63K ﹤0.01% 3325
2014
Q3 		– Sell
-707,077
Closed -$9.23M – 3401
2014
Q2 		$9.23M Buy
707,077
+257,597
+57% +$3.65M 0.01% 910
2014
Q1 		$9.66M Buy
+449,480
New +$8.08M 0.01% 872

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

AllianceBernstein's ABUS Position: Q1 2026 in Review

AllianceBernstein reduced its Arbutus Biopharma (ABUS) stake by 11% in Q1 2026, selling an estimated $72.3K and leaving 127,340 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

AllianceBernstein first reported a position in ABUS in Q1 2014 and has held it in 25 quarters since. The position peaked at $9.66M in Q1 2014. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • AllianceBernstein held 127,340 shares of Arbutus Biopharma worth $613K as of Q1 2026.
  • AllianceBernstein sold 16,530 Arbutus Biopharma shares in Q1 2026, an estimated $72.3K.
  • Arbutus Biopharma made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2539 holding.
  • AllianceBernstein first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 25 quarters since.
  • AllianceBernstein's Arbutus Biopharma position peaked at $9.66M in Q1 2014.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.